Glucagon analogue - AmideBio
Alternative Names: Long-acting glucagon - AmideBioLatest Information Update: 03 Nov 2022
At a glance
- Originator AmideBio
- Class Antihypoglycaemics; Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Congenital hyperinsulinism
Most Recent Events
- 04 Oct 2022 AmideBio receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for Glucagon analogue development in Congenital hyperinsulinism
- 04 Oct 2022 Preclinical trials in Congenital-hyperinsulinism in USA (unspecified route) (Before October,
- 04 Oct 2022 AmideBio plans to file for orphan drug and rare pediatric disease designations with the FDA Congenital hyperinsulinism